Plain-English translation of NCT06354088 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This research study is testing a medication called alpelisib to understand how it affects the way your body makes and stores fat. Researchers want to know whether the medication changes how your liver produces fat, especially in people who have trouble responding to insulin (a hormone that helps control blood sugar). You would receive either the real medication or a placebo (dummy pill) during two separate hospital stays.
Many people with prediabetes and fatty liver disease have trouble responding to insulin, which may lead to excessive fat buildup in the liver. Scientists don't fully understand why this happens, and this study aims to unlock that mystery so doctors can better treat these conditions.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would be admitted to a hospital research unit twice, with 2 to 8 weeks between visits. During each overnight stay, you would take either the study medication or a placebo in the evening, then receive special glucose solutions through an IV to help researchers measure how your body makes and processes fat. Blood samples would be drawn at set times, and the next day you would eat standardized meals while researchers continue monitoring your metabolism. The whole process takes about a day and a half per visit.
AI-generated summary from trial data Β· Jun 6, 2026 Β· Not medical advice
United States